Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.
about
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activationTaming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effectsMultiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in ratsNatural Phytochemicals in the Treatment and Prevention of Dementia: An OverviewVascular targets for cannabinoids: animal and human studiesIs the cardiovascular system a therapeutic target for cannabidiol?CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune DysregulationEndocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development.Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation.Correlation Between Cannabidiol-Induced Reduction of Infarct Volume and Inflammatory Factors Expression in Ischemic Stroke Model.Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder.Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm.Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusionCannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.Medical use of cannabis. Cannabidiol: a new light for schizophrenia?Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.Cannabinoids in experimental stroke: a systematic review and meta-analysis.The role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae).Neuroinflammation and neuroimmune dysregulation after acute hypoxic-ischemic injury of developing brainCannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activationCannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.Anandamide: an update.The complications of promiscuity: endocannabinoid action and metabolismModulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury.Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion modelDrug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications.Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT).Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol.Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?Role of adenosine in diabetic retinopathy.Cannabinoids: new promising agents in the treatment of neurological diseases.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.The potential role of cannabinoids in epilepsy treatment.Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.Molecular Pharmacology of Phytocannabinoids.
P2860
Q24605572-9507651E-9B3C-469A-A82F-3FFA21D8C30DQ24606148-8D79866D-A073-4E30-9DAB-7F70837F474AQ24623179-A48BFB85-212A-49C1-8B6B-ED4D7DFA4EBFQ24644922-DA279A10-6EC8-4606-9E8F-86D8A511D611Q26750581-8D296879-2370-4819-AD13-A958F6A4FD73Q26862515-85B03443-42B0-449F-9F4E-B2A496783376Q26865370-2C134153-3930-426E-8B54-E255C7C1CEDAQ28072822-9E3EA0AF-72E7-44E3-A4EA-D785EE391F05Q30473707-11001C33-D6D1-4A96-8F63-773F1E09871CQ30497010-49A9C09D-31FB-4FEF-A29A-AAAD0CC69163Q33690796-2A233FD1-4DED-4D91-81F4-E52B89A025B8Q33716712-1887FF07-8AEA-4F45-ACB3-D234028C2A47Q33897251-B6BBF581-618D-4B55-8A01-0F9561C5E2C4Q34028554-6FCCDF0B-F355-46A2-98AC-6BF61A6E5D4DQ34113027-83804842-58B7-4500-84E7-00593DA006FCQ34192001-FF95BDC0-2438-4256-BA64-68FBE950FBA5Q34308885-38A1AA1D-FF9F-4CE0-9CB2-859EC99706D6Q34402827-0FC0CD41-63A9-4B14-AD3A-EB185954D72EQ34452972-B917B89F-7A51-44AA-AE36-2EA53D9B59B6Q34910131-FA903FB6-DD8E-404F-9CB4-28675F70F1C3Q34954213-2375C6B6-CC9C-4C8D-B0EF-68DDA1F6E895Q35966006-1C2212A8-5DEE-41FC-A07B-E1D8195F48EDQ36176491-4E33E7BF-BF01-4EDC-AFFC-C941B6333E46Q36709628-8573355B-428E-448A-A433-F64107E613EEQ36944706-A14C4D82-4FB0-47D9-8F5C-56389EE0FD4AQ36961126-806AFD50-F53A-4F5F-852D-74217F6EC613Q37087780-253149BC-8FD4-4BCA-A1B4-A3C9C4ED0746Q37211892-EBFFDED8-9DDF-42AC-9BDE-AE3A12F16D3AQ37285921-239B1E91-234B-4A6F-B702-70DA33E82E6EQ37357596-165C6152-C4DF-4FDC-AF52-D1E4EAAAA63FQ37358669-F72C99FA-B42A-4BCA-8E07-873FE7A3E123Q37662551-DC57440A-9626-4AE6-AB74-BFB9CB57C04DQ37871350-ED237226-7A6B-4DC6-BF50-9CF8B6F134BFQ38012845-BC863EB9-3B0D-417E-88E8-F49F89ABEC2EQ38073250-3B1B78A9-1C7F-4258-89AC-997CBD4EE2DDQ38269376-4F34CFE7-E55B-435C-A1B5-99F418C73DF2Q38563981-35D0BAFB-4EAB-47F5-A1F8-31B4EE4D0C5DQ38606080-65302E6E-453B-440C-AACC-3D9D966F774DQ38974387-098DF5E3-0993-4594-80D8-171D9CFCD23CQ39102188-987F6014-F37D-4E5E-8BB2-0E8D945D075F
P2860
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@ast
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@en
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@nl
type
label
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@ast
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@en
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@nl
prefLabel
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@ast
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@en
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@nl
P2093
P921
P1433
P1476
Cannabidiol prevents cerebral ...... receptor-dependent mechanism.
@en
P2093
Katsunori Iwasaki
Kazuhide Hayakawa
Kenichi Mishima
Michihiro Fujiwara
Nobuaki Egashira
Tomoaki Ikeda
P304
P356
10.1161/01.STR.0000163083.59201.34
P407
P577
2005-04-21T00:00:00Z